TP53 mutations in Pap test DNA are a potential biomarker of ovarian cancer risk in high-risk women (226)
Talayeh Ghezelayagh(University of Washington), Rosana Risques(University of Washington), Barbara M. Norquist(University of Washington), Enna Manhardt(University of Washington), Marc R. Radke(University of Washington), Brendan F. Kohrn(University of Washington), Elizabeth M. Swisher(University of Washington), Ronit Katz(University of Washington), Jeanne Fredrickson(University of Washington), Jeffrey D. Krimmel‐Morrison(University of Washington)
Cited by 0
Related Papers
Cystatin C versus Creatinine in Determining Risk Based on Kidney Function
|New England Journal of Medicine|2013|968
Telomere-to-telomere assembly of a complete human X chromosome
|Nature|2020|842
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017
|Journal of the National Comprehensive Cancer Network|2016|660
Multiple loci associated with indices of renal function and chronic kidney disease
|Nature Genetics|2009|658
Genetic/Familial High-Risk Assessment: Breast and Ovarian
|Journal of the National Comprehensive Cancer Network|2010|650